The expression of therapy-related CD14+ monocytes in these groups was significantly different, which suggests that the activation of AP-1 family and the therapy-related CD14+ monocytes may help identify and screen heart failure patients suitable for the MSCs therapy. This evidence concerns the gene JUN and heart failure.